Influence of 8 Weeks of Tabata High-Intensity Interval Training and Nanocurcumin Supplementation on Inflammation and Cardiorespiratory Health Among Overweight Elderly Women
Overview
Affiliations
Nanocurcumin (NaC) and high-intensity interval training (HIIT) play crucial role in weight and inflammation control. The purpose of the current study was to evaluate the separate and combined effects of 8 weeks of Tabata-HIIT and NaC supplementation on the NOD-like receptor family pyrin domain-containing 3 () inflammasome, long non-coding RNA myocardial infarction associated transcript () expression, body composition, and cardiorespiratory health in elderly overweight women. A total of 48 healthy overweight elderly women were randomly divided into four groups: NaC, Tabata-HIIT+Pla, Tabata-HIIT+NaC, and placebo. Participants underwent a Tabata HIIT program (2 days per week, at 80∼0% of maximal HR) and NaC supplementation (daily 80 mg in two 40 mg capsules) for 8 weeks. Blood sampling, cardiorespiratory hemodynamic responses, and body composition evaluations were obtained before and after treadmill stress testing at the baseline timepoint and following 8 weeks of intervention. The mRNA of and were measured by real-time polymerase chain reaction. After 8 weeks, a significant improvement was observed in body composition and cardiorespiratory hemodynamics in the Tabata-HIIT groups compared to the NaC alone and placebo groups (<0.05). Tabata training, both with and without the addition of nano curcumin supplementation, did not result significant effect on the resting levels of expression (>0.05). Nevertheless, NaC supplementation along with Tabata training led to a significant reduction in inflammasome. In addition, NaC supplementation in overweight/preobese women improved systemic inflammation during treadmill stress testing. These findings indicating the suppressive effects of non-pharmacologic interventions on the sympathetic system and downregulation of the inflammasome.
Hajimirzaei P, Eyni H, Razmgir M, Abolfazli S, Pirzadeh S, Ahmadi Tabatabaei F Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):393-416.
PMID: 39186190 DOI: 10.1007/s00210-024-03369-0.